SCHEMBL3378891

SCHEMBL3378891

CS(=O)(=O)Nc1ccc(-c2cccc(F)c2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.52
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2D6 P10635 3/20 0.47
CLK4 Q9HAZ1 2/20 0.47
ALDH1A1 P00352 2/20 0.47
ALOX15 P16050 2/20 0.47
TSHR P16473 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 2/20 0.47
GAA P10253 1/20 0.47
KCNA5 P22460 1/20 0.45
KCNH2 Q12809 1/20 0.45
KIF11 P52732 2/20 0.44
CYP17A1 P05093 1/20 0.43
MET P08581 1/20 0.43
USP2 O75604 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374111 0.87 GAA (0.50) HPGDMAPK1GAAKCNH2KIF11
SCHEMBL3379995 0.86 PGR (0.51) HPGDMAPK1GAAKIF11CYP17A1
SCHEMBL3378764 0.84 PTGS2 (0.51) CYP1A2CYP3A4CYP2D6CLK4ALDH1A1
SCHEMBL3375774 0.84 GAA (0.52) HPGDMAPK1GAAKIF11CYP17A1
SCHEMBL3375688 0.83 KIF11 (0.56) CYP1A2CYP3A4HPGDMAPK1GAA
SCHEMBL3376954 0.82 KIF11 (0.48) HPGDMAPK1GAAKCNH2KIF11
SCHEMBL3374747 0.82 KIF11 (0.51) ALDH1A1HPGDMAPK1GAAKIF11
SCHEMBL3377083 0.82 PTGS2 (0.52) ALDH1A1TSHRHPGDMAPK1GAA
SCHEMBL3379785 0.80 GAA (0.49) HPGDMAPK1GAAKCNH2KIF11
SCHEMBL3377007 0.80 KIT (0.51) HPGDMAPK1GAAKIF11CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 SLC22A12 716/4885CYP1A2 1827/4885CYP3A4 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.